Regulatory agencies have recently discouraged the prescription of topiramate (TPM) to women of childbearing potential with epilepsy due to growing evidence of the teratogenic and neurodevelopmental risks associated with its use during pregnancy. It remains, however, unclear whether the use of TPM in this population can be supported to some extent by its high effectiveness. In this multicenter, retrospective, cohort study performed at 22 epilepsy centers, we investigated the comparative effectiveness of TPM and levetiracetam (LEV) given as first-line antiseizure medication in a cohort of women of childbearing potential with idiopathic generalized epilepsy (IGE). A total of 336 participants were included, of whom 24 (7.1%) received TPM and 312 (92.9%) LEV. Women treated with TPM had significantly higher risks of treatment failure and treatment withdrawal and were less likely to achieve seizure freedom at 12 months compared to women treated with LEV. In conclusion, this study highlighted a low tendency among clinicians to use TPM in women of childbearing potential with IGE, anticipating the recently released restrictions on its use. Furthermore, the available data on effectiveness do not appear to support the use of TPM in this population.
Topiramate ban in women of childbearing potential with idiopathic generalized epilepsy: Does effectiveness offset the teratogenic risks? / Cerulli Irelli, Emanuele; Cocchi, Enrico; Mostacci, Barbara; Orlando, Biagio; Gesche, Joanna; Caraballo, Roberto H; Lattanzi, Simona; Strigaro, Gionata; Catania, Cecilia; Pulitano, Patrizia; Panzini, Chiara; Ferlazzo, Edoardo; Pascarella, Angelo; Casciato, Sara; Pizzanelli, Chiara; Giuliano, Loretta; Viola, Veronica; Fortunato, Francesco; Di Gennaro, Giancarlo; Gambardella, Antonio; Labate, Angelo; Operto, Francesca F; Giallonardo, Anna T; Baykan, Betul; Beier, Christoph P; Di Bonaventura, Carlo. - In: EPILEPSIA. - ISSN 1528-1167. - 65:3(2024), pp. 27-34. [10.1111/epi.17892]
Topiramate ban in women of childbearing potential with idiopathic generalized epilepsy: Does effectiveness offset the teratogenic risks?
Lattanzi, Simona;
2024-01-01
Abstract
Regulatory agencies have recently discouraged the prescription of topiramate (TPM) to women of childbearing potential with epilepsy due to growing evidence of the teratogenic and neurodevelopmental risks associated with its use during pregnancy. It remains, however, unclear whether the use of TPM in this population can be supported to some extent by its high effectiveness. In this multicenter, retrospective, cohort study performed at 22 epilepsy centers, we investigated the comparative effectiveness of TPM and levetiracetam (LEV) given as first-line antiseizure medication in a cohort of women of childbearing potential with idiopathic generalized epilepsy (IGE). A total of 336 participants were included, of whom 24 (7.1%) received TPM and 312 (92.9%) LEV. Women treated with TPM had significantly higher risks of treatment failure and treatment withdrawal and were less likely to achieve seizure freedom at 12 months compared to women treated with LEV. In conclusion, this study highlighted a low tendency among clinicians to use TPM in women of childbearing potential with IGE, anticipating the recently released restrictions on its use. Furthermore, the available data on effectiveness do not appear to support the use of TPM in this population.File | Dimensione | Formato | |
---|---|---|---|
Irelli_Topiramate-ban-women-childbearing_2024.pdf
Solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza d'uso:
Tutti i diritti riservati
Dimensione
1.59 MB
Formato
Adobe PDF
|
1.59 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.